Clinical trial
Study of a New Protease Inhibitor, BMS-232632, in Combination With Other…
NCT00002240 · Bristol-Myers Squibb, Industry · Completed
Key facts
| NCT number | NCT00002240 |
|---|---|
| Title | Study of a New Protease Inhibitor, BMS-232632, in Combination With Other Anti-HIV Drugs |
| Official title | Evaluation of the Safety and Antiviral Efficacy of a Novel HIV-1 Protease Inhibitor, BMS-232632, Alone and in Combination With d4T and ddI as Compared to a Reference Combination Regimen |
| Lead sponsor | Bristol-Myers Squibb, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | HIV Infections |
| Intervention type | Drug |
| Interventions | Atazanavir, Nelfinavir mesylate, Stavudine, Didanosine |
| Start date | Mar 1, 1999 |
| Primary completion | Dec 1, 2001 |
| Completion | Dec 1, 2001 |
| First posted | Aug 31, 2001 |
| Last update posted | May 4, 2011 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: